CN105287561A - 一种治疗溃疡性结肠炎的药物组合物 - Google Patents
一种治疗溃疡性结肠炎的药物组合物 Download PDFInfo
- Publication number
- CN105287561A CN105287561A CN201510826741.XA CN201510826741A CN105287561A CN 105287561 A CN105287561 A CN 105287561A CN 201510826741 A CN201510826741 A CN 201510826741A CN 105287561 A CN105287561 A CN 105287561A
- Authority
- CN
- China
- Prior art keywords
- ulcerative colitis
- nicotinic acid
- treatment
- effect
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 29
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 76
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 38
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 38
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 25
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000282 metronidazole Drugs 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 9
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 9
- 235000019698 starch Nutrition 0.000 claims abstract description 9
- 239000008107 starch Substances 0.000 claims abstract description 9
- 229940032147 starch Drugs 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 12
- 229940095399 enema Drugs 0.000 abstract description 11
- 239000007920 enema Substances 0.000 abstract description 11
- 241000792859 Enema Species 0.000 abstract description 10
- 206010009887 colitis Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 5
- 210000001072 colon Anatomy 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 10
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010061926 Purulence Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 238000012321 colectomy Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗溃疡性结肠炎的药物组合物,所述组合物包括生理盐水,甲硝唑,淀粉,烟酸和***。本发明的优点在于,将几种临床常用的治疗其他疾病或者溃疡性结肠炎的常用药物组合成配方,采用保留灌肠局部治疗,可以给对传统口服或灌肠治疗药物效果不佳或者口服产生副作用较大的全结肠或左半结肠炎患者带来显著的治疗效果。此配方药为临床老药新用,价格实惠。对常规传统治疗溃疡性结肠炎药物不敏感的患者,采用此配方药治疗效果明显,且此配方药副作用较小。
Description
技术领域
本发明属于医学领域,更具体地讲,涉及一种治疗溃疡性结肠炎的药物组合物。
背景技术
目前治疗溃疡性结肠炎患者的药物主要分口服用药和局部灌肠两类。口服用药包括氨基水杨酸类、激素、免疫抑制药及新兴的生物制剂,局部用药包括氨基水杨酸类的栓剂及灌肠剂和激素类的灌肠剂。目前常用药物氨基水杨酸类、激素、免疫抑制药容易耐受,副作用较大,多数患者病情迁延不愈,容易复发。新兴的生物制剂价格昂贵。
烟酸是一种临床常见药物,主要用于治疗糙皮病,目前也用于调节血脂的治疗。但是在消化道疾病的治疗中目前没有报道。
发明内容
本发明的第一个目的在于提供烟酸在制备治疗溃疡性结肠炎药物中的应用。
本发明的第二个目的在于提供一种治疗溃疡性结肠炎的药物组合物。
为实现本发明第一个目的,本发明公开以下技术方案:烟酸在制备治疗溃疡性结肠炎药物中的应用。
为实现本发明第二个目的,本发明公开以下技术方案:一种治疗溃疡性结肠炎的药物组合物,其特征在于,所述组合物包括生理盐水,甲硝唑,淀粉,烟酸和***。
作为一个优选方案,治疗溃疡性结肠炎的药物组合物中各组分含量为:生理盐水100-200ml,甲硝唑0.5-1g,淀粉5-10g,烟酸300-400mg,***5-10mg。
本发明的优点在于:将几种临床常用的治疗其他疾病或者溃疡性结肠炎的常用药物组合成配方,采用保留灌肠局部治疗,可以给对传统口服或灌肠治疗药物效果不佳或者口服药物产生副作用较大的全结肠或左半结肠炎患者带来显著的治疗效果。此配方药为临床老药新用,价格实惠。对常规治疗溃疡性结肠炎药物不敏感的患者,采用此配方药治疗效果明显,且此配方药副作用较小。
附图说明
图1为饲喂烟酸之后小鼠体内PGD2的合成代谢情况。
图2为用DSS诱导小鼠结肠炎模型,检测烟酸对溃疡性结肠炎的治疗作用,通过PGD2信号通路激活,烟酸改善了DSS引起的体重减轻(A),降低了疾病活动指数(B),也减轻了小鼠结肠的炎症性挛缩水肿(C)。
图3为烟酸对DSS处理的小鼠的生存率的影响。
图4为结肠炎患者在用烟酸灌肠后尿液中PGD2的代谢产物。
图5为全结肠炎患者加用烟酸保留灌肠后的治疗效果(肠镜),其中A为初次诊断时的肠镜图片(溃疡、出血、表面有脓性白苔),B为传统口服和灌肠治疗溃疡性结肠炎药物治疗后,效果不好,病情无缓解,C为加用烟酸保留灌肠治疗后,患者的病情明显缓解,肠镜下黏膜完全修复(溃疡修复、黏膜可见毛细血管等)。
图6为另一左半结肠炎患者加用烟酸灌肠后的治疗效果(肠镜),其中A为初次诊断时的肠镜图片(溃疡、出血、表面有脓性白苔),B为传统口服和灌肠治疗溃疡性结肠炎药物治疗后,效果不好,病情无缓解,C为加用烟酸治疗后,患者的病情明显缓解,肠镜下黏膜完全修复(溃疡修复、黏膜可见毛细血管等)。
图7为患者的mayo评分。
具体实施方式
下面结合具体实施例,进一步阐述本发明。下述实施例中所使用的实验方法如无特殊说明,均为常规方法。下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。
实施例1.烟酸对溃疡性结肠炎的治疗作用
小鼠实验:(Niacin用法:600mg/kg一天一次灌胃)
1.Niacin(烟酸)是一种临床常用治疗糙皮病的药物,也具有调节血脂的作用。有研究报道它能够促进PGD2的释放,我们前期的基础研究证实PGD2在溃疡性结肠炎的发生发展中具有一定的保护作用。
首先,我们检测饲喂烟酸之后,小鼠体内PGD2的合成代谢情况,结果如图1:饲喂烟酸之后,小鼠尿液中PGD2的代谢产物增多,结肠组织中PGD2的合成也增多。
2.用DSS诱导小鼠结肠炎模型,检测烟酸对溃疡性结肠炎的治疗作用。
(1)在DP1正常表达的情况下,烟酸可以通过上调PGD2/DP1信号通路抑制肠炎的发生。具体体现在抑制DSS诱导的小鼠体重的减轻、疾病活动指数的恶化及小鼠结肠的炎性挛缩。具体参见图2。
(2)我们也检测了烟酸对DSS处理的小鼠的生存率的影响,结果如图3所示,在PGD2/DP1信号通路存在的条件下,烟酸抑制DSS引起的小鼠的死亡。
通过以上动物实验,我们得到的结论是烟酸可以通过PGD2/DP1信号通路抑制溃疡性结肠炎的发生发展。
实施例2.药物组合物临床试验
将几类药物按照一定的比例组合成配方,采用保留灌肠的方式对溃疡性结肠炎患者进行治疗。配方如下:生理盐水100-200ml甲硝唑0.5-1g淀粉5-10g烟酸300-400mg***5-10mg。
含甲硝唑的配方用2周,继续用不含甲硝唑的配方2-4周。
我们接下来选取了数十例对常规治疗药物不敏感或无效全结肠或左半结肠溃疡性结肠炎患者,在其知情同意下加用烟酸灌肠治疗,4-6周后复查血及肠镜,观察其疗效。所选患者用烟酸灌肠前都用过传统的灌肠治疗,具体药物(生理盐水、甲硝唑、淀粉、***)结果如图4,加用保留烟酸灌肠后,患者的症状明显改善。
(1)如同上述动物实验,结肠炎患者在用烟酸灌肠后尿液中PGD2的代谢产物也是增加的。
(2)图5和图6为两个患者加用烟酸灌肠后的治疗效果(肠镜)。
图5为患者一(生理盐水200ml,甲硝唑1g,淀粉10g,烟酸400mg,***10mg),其中A为初次诊断时的肠镜图片(溃疡、出血、表面有脓性白苔),B为传统口服和灌肠治疗溃疡性结肠炎药物治疗后,效果不好,病情无缓解,C为加用烟酸治疗后,患者的病情明显缓解,肠镜下黏膜完全修复(溃疡修复、黏膜可见毛细血管等)。
图6为患者二(生理盐水100ml,甲硝唑0.5g,淀粉5g,烟酸300mg,***5mg)的肠镜结果。
我们也统计了患者的mayo评分,结果如图7所示,患者在加用烟酸保留灌肠后,患者的mayo评分明显降低了,代表烟酸对溃疡性结肠炎患者具有显著的保护作用。
本发明药物组合物可以治疗对常规口服和灌肠治疗溃疡性结肠炎药物不敏感的患者;配方中的药物均为临床治疗其他疾病或肠炎的常用药物,技术较成熟;此配方中的药物及采用的治疗方式所带来的副作用较小。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (3)
1.烟酸在制备治疗溃疡性结肠炎药物中的应用。
2.一种治疗溃疡性结肠炎的药物组合物,其特征在于,所述组合物包括生理盐水,甲硝唑,淀粉,烟酸和***。
3.根据权利要求2所述的一种治疗溃疡性结肠炎的药物组合物,其特征在于,各组分含量为:生理盐水100-200ml,甲硝唑0.5-1g,淀粉5-10g,烟酸300-400mg,***5-10mg。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510826741.XA CN105287561A (zh) | 2015-11-25 | 2015-11-25 | 一种治疗溃疡性结肠炎的药物组合物 |
CN201610898805.1A CN106562967A (zh) | 2015-11-25 | 2016-10-14 | 一种治疗溃疡性结肠炎的药物组合物 |
PCT/CN2016/106870 WO2017088749A1 (zh) | 2015-11-25 | 2016-11-23 | 一种治疗溃疡性结肠炎的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510826741.XA CN105287561A (zh) | 2015-11-25 | 2015-11-25 | 一种治疗溃疡性结肠炎的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105287561A true CN105287561A (zh) | 2016-02-03 |
Family
ID=55185851
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510826741.XA Pending CN105287561A (zh) | 2015-11-25 | 2015-11-25 | 一种治疗溃疡性结肠炎的药物组合物 |
CN201610898805.1A Pending CN106562967A (zh) | 2015-11-25 | 2016-10-14 | 一种治疗溃疡性结肠炎的药物组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610898805.1A Pending CN106562967A (zh) | 2015-11-25 | 2016-10-14 | 一种治疗溃疡性结肠炎的药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN105287561A (zh) |
WO (1) | WO2017088749A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017088749A1 (zh) * | 2015-11-25 | 2017-06-01 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
CN106860463A (zh) * | 2017-02-15 | 2017-06-20 | 沂南县迎辉农业开发有限公司 | 一种降低醋酸***片临床副作用的药剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115105514B (zh) * | 2022-06-14 | 2024-03-15 | 邯郸制药股份有限公司 | 一种保护胃黏膜、治疗胃溃疡的药物组合物及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1208652A (zh) * | 1998-08-30 | 1999-02-24 | 李金峰 | 一种治疗结肠疾病的药物 |
CN1180775C (zh) * | 2002-07-29 | 2004-12-22 | 李延 | 复方口腔溃疡胶囊 |
GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
CN101505748A (zh) * | 2006-07-17 | 2009-08-12 | 汤玛士·克利斯秦·赖斯 | 含斛皮素组合物 |
JP6855165B2 (ja) * | 2012-06-15 | 2021-04-07 | コナリス リサーチ インスティチュート アーゲー | ニコチン酸および/もしくはニコチンアミドならびに/またはトリプトファンを含有する、腸内微生物叢によい影響を及ぼすための医薬組成物 |
MX2016007323A (es) * | 2013-12-13 | 2016-09-09 | Conaris Res Inst Ag | Una composicion farmaceutica que contiene combinaciones de nicotinamida y acido 5-aminosalicilico para influir beneficiosamente en la microflora intestinal y/o para tratar la inflamacion gastrointestinal. |
CN105287561A (zh) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
-
2015
- 2015-11-25 CN CN201510826741.XA patent/CN105287561A/zh active Pending
-
2016
- 2016-10-14 CN CN201610898805.1A patent/CN106562967A/zh active Pending
- 2016-11-23 WO PCT/CN2016/106870 patent/WO2017088749A1/zh active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017088749A1 (zh) * | 2015-11-25 | 2017-06-01 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
CN106860463A (zh) * | 2017-02-15 | 2017-06-20 | 沂南县迎辉农业开发有限公司 | 一种降低醋酸***片临床副作用的药剂 |
Also Published As
Publication number | Publication date |
---|---|
CN106562967A (zh) | 2017-04-19 |
WO2017088749A1 (zh) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schilling et al. | Sedation with propofol for interventional endoscopy by trained nurses in high-risk octogenarians: a prospective, randomized, controlled study | |
ES2680921T3 (es) | Tetrahidrocannabivarina para uso en el tratamiento de enfermedades inflamatorias intestinales | |
Kimura et al. | Treatment of delirium with ramelteon: initial experience in three patients | |
Cotton et al. | Unexpected extra‐renal effects of loop diuretics in the preterm neonate | |
Epstein et al. | The unappreciated role of extrarenal and gut sensors in modulating renal potassium handling: implications for diagnosis of dyskalemias and interpreting clinical trials | |
Haddadi et al. | Comparing the duration of the analgesic effects of intravenous and rectal acetaminophen following tonsillectomy in children | |
Cao et al. | Rapid rehabilitation technique with integrated traditional Chinese and Western medicine promotes postoperative gastrointestinal function recovery | |
CN105287561A (zh) | 一种治疗溃疡性结肠炎的药物组合物 | |
CN104337916A (zh) | 一种手脚冰凉及脚气的中药药剂 | |
Brotfain et al. | Iodine‐Induced Hyperthyroidism—An Old Clinical Entity That Is Still Relevant to Daily ICU Practice: A Case Report | |
CN105902558B (zh) | 一种药物组合物及其制备方法和应用 | |
CN103479970B (zh) | 一种治疗风湿性关节痛的外用药物 | |
Yu et al. | Severe adverse reactions caused by omeprazole: a case report | |
Lofty et al. | Intralesional combined furosemide and digoxin in cutaneous warts treatment: A randomized controlled clinical trial | |
Yin et al. | Smartband use during enhanced recovery after surgery facilitates inpatient recuperation following minimally invasive colorectal surgery | |
Lin et al. | Effects of rhubarb peony decoction combined with antibiotics in treating pediatric periappendiceal abscess | |
Qiu et al. | Proton pump inhibitor‑induced exfoliative dermatitis: A case report | |
Byrne et al. | Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes–A note of caution | |
CN106361737A (zh) | 曲尼司特在制备治疗结核病的药物中的应用 | |
Chang et al. | Resolution of a vocal fold polyp treated with Chinese herbal medicine: One case report with literature review | |
JP2009263384A (ja) | I型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬 | |
Hoang et al. | Zinc Iodide-Dimethyl Sulfoxide Composition in Treatment of Chronic Respiratory Diseases | |
CN106177852A (zh) | 一种用于治疗脚气病的中药 | |
CN105816862A (zh) | 乌司他丁在制备治疗***癌药物中的用途 | |
Sands | Recent and Near Future Advances in Medical Therapy for the Inflammatory Bowel Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |